The IL-2RG R328X nonsense mutation allows partial STAT-5 phosphorylation and defines a critical region involved in the leaky-SCID phenotype.


Journal

Clinical and experimental immunology
ISSN: 1365-2249
Titre abrégé: Clin Exp Immunol
Pays: England
ID NLM: 0057202

Informations de publication

Date de publication:
04 2020
Historique:
accepted: 28 11 2019
pubmed: 5 12 2019
medline: 28 7 2020
entrez: 5 12 2019
Statut: ppublish

Résumé

In addition to their detection in typical X-linked severe combined immunodeficiency, hypomorphic mutations in the interleukin (IL)-2 receptor common gamma chain gene (IL2RG) have been described in patients with atypical clinical and immunological phenotypes. In this leaky clinical phenotype the diagnosis is often delayed, limiting prompt therapy in these patients. Here, we report the biochemical and functional characterization of a nonsense mutation in exon 8 (p.R328X) of IL2RG in two siblings: a 4-year-old boy with lethal Epstein-Barr virus-related lymphoma and his asymptomatic 8-month-old brother with a T

Identifiants

pubmed: 31799703
doi: 10.1111/cei.13405
pmc: PMC7066387
doi:

Substances chimiques

Codon, Nonsense 0
IL2RG protein, human 0
Interleukin Receptor Common gamma Subunit 0
STAT5 Transcription Factor 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

61-72

Informations de copyright

© 2019 British Society for Immunology.

Références

Blood. 1997 Mar 15;89(6):1968-77
pubmed: 9058718
J Clin Invest. 1995 Mar;95(3):1169-73
pubmed: 7883965
Chem Biol. 2011 Mar 25;18(3):314-23
pubmed: 21439476
J Allergy Clin Immunol. 2016 Mar;137(3):940-2.e4
pubmed: 26525228
Hum Mutat. 2004 May;23(5):522-3
pubmed: 15108287
J Clin Invest. 1997 Dec 15;100(12):3036-43
pubmed: 9399950
J Clin Invest. 1990 Nov;86(5):1623-31
pubmed: 2243135
Genes Cells. 1999 Jun;4(6):363-73
pubmed: 10421845
Hum Mol Genet. 1993 Aug;2(8):1099-104
pubmed: 8401490
Clin Exp Immunol. 2002 Sep;129(3):502-9
pubmed: 12197892
Immunol Rev. 2004 Dec;202:67-83
pubmed: 15546386
Allergy Asthma Clin Immunol. 2019 Jan 5;15:2
pubmed: 30622570
Science. 1992 Jul 17;257(5068):379-82
pubmed: 1631559
Cell. 1993 Apr 9;73(1):147-57
pubmed: 8462096
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S182-94
pubmed: 20042228
Front Immunol. 2019 Apr 05;10:722
pubmed: 31024554
Blood. 2008 Nov 15;112(10):4090-7
pubmed: 18728247
J Clin Immunol. 2015 Oct;35(7):610-4
pubmed: 26407811
Science. 1994 Nov 11;266(5187):1042-5
pubmed: 7973658
J Allergy Clin Immunol. 2011 Dec;128(6):1360-1363.e4
pubmed: 21831415
Pediatr Blood Cancer. 2014 Jan;61(1):178-9
pubmed: 23940110
Hosp Med. 2002 Nov;63(11):676-80
pubmed: 12474613
Science. 1994 Nov 11;266(5187):1045-7
pubmed: 7973659
J Allergy Clin Immunol. 2009 Feb;123(2):505-8
pubmed: 19203666
Clin Immunol. 2011 Oct;141(1):73-82
pubmed: 21664875
Biochemistry. 2002 Jul 9;41(27):8725-31
pubmed: 12093291
Immunol Invest. 2004 May;33(2):109-42
pubmed: 15195693
Adv Exp Med Biol. 2001;495:199-204
pubmed: 11774567
Clin Immunol. 2000 Apr;95(1 Pt 1):39-50
pubmed: 10794431
Immunogenetics. 2017 Jan;69(1):29-38
pubmed: 27566612
Hum Mutat. 2019 Jul;40(7):865-878
pubmed: 31026367
Eur J Immunol. 2014 Oct;44(10):3129-40
pubmed: 25042067
Front Immunol. 2017 Jul 12;8:808
pubmed: 28747913
Clin Immunol. 2000 Apr;95(1 Pt 1):33-8
pubmed: 10794430
J Clin Immunol. 2015 Jul;35(5):449-53
pubmed: 26076747
Mol Cell Biol. 1996 Jan;16(1):309-17
pubmed: 8524310
Front Pediatr. 2019 Feb 04;7:15
pubmed: 30778380
J Pediatr. 2005 Oct;147(4):555-7
pubmed: 16227049
Nat Rev Immunol. 2003 Apr;3(4):269-79
pubmed: 12669018
J Pediatr Hematol Oncol. 2019 May;41(4):328-333
pubmed: 29939941
Cytometry B Clin Cytom. 2019 May;96(3):223-233
pubmed: 30334372

Auteurs

A Arcas-García (A)

CIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group, Institut de Recerca Vall d'Hebron (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

M Garcia-Prat (M)

Jeffrey Model Foundation Excellence Center, Barcelona, Spain.
Pediatric Infectious Diseases and Immunodeficiencies Unit, Vall d'Hebron Campus Hospitalari, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

M Magallón-Lorenz (M)

CIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group, Institut de Recerca Vall d'Hebron (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

A Martín-Nalda (A)

Jeffrey Model Foundation Excellence Center, Barcelona, Spain.
Pediatric Infectious Diseases and Immunodeficiencies Unit, Vall d'Hebron Campus Hospitalari, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

O Drechsel (O)

Center for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.

S Ossowski (S)

Center for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.

L Alonso (L)

Jeffrey Model Foundation Excellence Center, Barcelona, Spain.
Hematopoietic Stem Cell Transplantation Unit, Pediatric Hematology and Oncology Department, Vall d'Hebron Campus Hospitalari, Barcelona, Spain.

J G Rivière (JG)

Jeffrey Model Foundation Excellence Center, Barcelona, Spain.
Pediatric Infectious Diseases and Immunodeficiencies Unit, Vall d'Hebron Campus Hospitalari, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

P Soler-Palacín (P)

Jeffrey Model Foundation Excellence Center, Barcelona, Spain.
Pediatric Infectious Diseases and Immunodeficiencies Unit, Vall d'Hebron Campus Hospitalari, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

R Colobran (R)

Jeffrey Model Foundation Excellence Center, Barcelona, Spain.
Immunology Division, Department of Cell Biology, Physiology and Immunology, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Genetics Department, Hospital Universitari Vall d'Hebron (HUVH), Barcelona, Spain.

J Sayós (J)

CIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group, Institut de Recerca Vall d'Hebron (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

M Martínez-Gallo (M)

Jeffrey Model Foundation Excellence Center, Barcelona, Spain.
Immunology Division, Department of Cell Biology, Physiology and Immunology, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

C Franco-Jarava (C)

Jeffrey Model Foundation Excellence Center, Barcelona, Spain.
Immunology Division, Department of Cell Biology, Physiology and Immunology, Hospital Universitari Vall d'Hebron (HUVH), Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH